Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spyre Therapeutics (SYRE) Research & Development: 2014-2024

Historic Research & Development for Spyre Therapeutics (SYRE) over the last 11 years, with Dec 2024 value amounting to $162.8 million.

  • Spyre Therapeutics' Research & Development rose 1.12% to $45.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $177.5 million, marking a year-over-year increase of 21.58%. This contributed to the annual value of $162.8 million for FY2024, which is 81.88% up from last year.
  • According to the latest figures from FY2024, Spyre Therapeutics' Research & Development is $162.8 million, which was up 81.88% from $89.5 million recorded in FY2023.
  • Spyre Therapeutics' 5-year Research & Development high stood at $162.8 million for FY2024, and its period low was $57.1 million during FY2021.
  • For the 3-year period, Spyre Therapeutics' Research & Development averaged around $103.6 million, with its median value being $89.5 million (2023).
  • As far as peak fluctuations go, Spyre Therapeutics' Research & Development declined by 7.68% in 2020, and later soared by 81.88% in 2024.
  • Over the past 5 years, Spyre Therapeutics' Research & Development (Yearly) stood at $59.6 million in 2020, then dropped by 4.31% to $57.1 million in 2021, then rose by 2.65% to $58.6 million in 2022, then soared by 52.79% to $89.5 million in 2023, then spiked by 81.88% to $162.8 million in 2024.